Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.

Oncogene - 21 Jan 2010

Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis C A, Norton L, Solit D B, Arribas J, Baselga J, Rosen N

Abstract excerpt

The anti-HER2 antibody Trastuzumab (Herceptin) has been proven to be effective in the treatment of HER2-overexpressing breast cancer; resistance, however, invariably emerges in metastatic tumors. The expression of p95-HER2, a form of HER2 with a truncated extracellular domain that lacks the Trast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3 Cells
Share to Antibodies, Monoclonal, Humanized
Share to Heterocyclic Compounds, 4 or More Rings

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Receptor, ErbB-2

Share to Trastuzumab

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 19855434
DOI: 10.1038/onc.2009.337
PMCID: PMC3057066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19855434-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.PMID 19855434Read ↗

HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA RepairSemantic proximity Read ↗

Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stabilitySemantic proximity Read ↗

p95HER2 and Breast CancerSemantic proximity Read ↗

HER2 signaling regulates HER2 localization and membrane retentionSemantic proximity Read ↗

Role of Erbin in ErbB2-dependent breast tumor growth.Semantic proximity Read ↗

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expressionSemantic proximity Read ↗

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab ResistanceSemantic proximity Read ↗

Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibitionSemantic proximity Read ↗

PP2A inhibition overcomes acquired resistance to HER2 targeted therapySemantic proximity Read ↗

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285Semantic proximity Read ↗

Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase InhibitorsSemantic proximity Read ↗

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.